恩度联合含培美曲塞方案治疗复发耐药骨肉瘤的临床效果探讨(1)
【摘 要】目的:探讨恩度联合含培美曲塞方案治疗复发耐药骨肉瘤的临床效果。方法:选取2014年4月-2018年4月我院收治的复发耐药骨肉瘤患者76例,随机分为两组,对照组应用培美曲塞药物治疗,研究组应用恩度联合含培美曲塞方案治疗。比较两组患者临床效果以及生活质量。结果:研究组治疗总有效率为76.31%,高于对照组的47.36%(P<0.05);研究组生活质量评分高于对照组(P<0.05)。结论:恩度联合含培美曲塞方案治疗复发耐药骨肉瘤的治疗有利于提高患者的生存率,而且提升了临床的效果,治疗效果非常理想,临床上应当进一步推广应用。【关键词】恩度;培美曲塞;治疗;复发;骨肉瘤
Abstract:Objective To investigate the clinical effect of Endo combined with pemetrexed regimen in the treatment of relapsed drug-resistant osteosarcoma. METHODS: Sixty-six patients with relapsed drug-resistant osteosarcoma admitted to our hospital from April 2014 to April 2018 were randomly divided into two groups. The control group was treated with pemetrexed. The study group was treated with Endo and Peimei. Qusay regimen treatment. The clinical effects and quality of life of the two groups were compared. Results: The total effective rate of the study group was 76.31% ......
您现在查看是摘要页,全文长 3594 字符。